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Abstract
Today, high-resolution mass spectrometry (HRMS: Q-TOF-MS, Orbitrap-MS) 
shows sensitive and reliable quantifications of a large variety of compounds while 
acquiring in high-resolution full-scan mode. Interestingly, HRMS shows equal 
quantitative performance than triple-quadrupole-MS (QQQ-MS), which is the 
MS technology traditionally used for quantification. But, in contrast to QQQ-MS 
that performs “narrow-minded” ion transitions (targeted prior determination), 
analysis using HRMS can record HR-full scan that detects virtually all ions (e.g., 
from m/z = 80 to 1000) and gives a global picture of what is in the biological sample 
(diagnostic screening). This is more and more seen as a key advantage because on 
top of targeted and quantitative analyses, many other routine or research deter-
minations can be performed such as qualitative (identification), simultaneous 
quantitative/qualitative (quan/qual), and omics (untargeted) assays. The high 
versatility and performance of most actual HRMS instruments placed them as new 
gold standards in LC-MS analysis. Indeed, only HRMS can answer new analytical 
requests from systems biology and personalized medicine requesting more holistic 
approaches with untargeted analyses (e.g., proteomics and metabolomics). In the 
light of the new HRMS-based paradigm, concrete examples revealing quantitative, 
qualitative, simultaneous quan/qual, and omics capabilities of HRMS in the context 
of routine and research analyses will be given.
Keywords: diagnostic, HRMS, high resolution, LC-MS, liquid chromatography, mass 
spectrometry, metabolomics, Orbitrap-MS, proteomics, quantitative, qualitative, 
routine, screening, Q-TOF-MS, triple-quadrupole-MS, untargeted
1. Introduction: analytical tools and the understanding of the biology
In life sciences, liquid chromatography coupled to mass spectrometry (LC-MS) 
is considered as a tool to measure molecules in biological samples. In clinical and 
toxicology labs, LC-MS determinations are quantitative and routinely performed 
and usually measured one or a few compounds [1–4]. These analyses are strongly 
driven by medical knowledge as well as the understanding of disease biology. 
Our understanding of the biology is, to a large extent, related to the available 
analytical tools. On the other hand, new concepts in life sciences can promote 
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the development of new analytical tools. The actual understanding of biological 
systems is presented here below. It will help to put into perspective the actual and 
future needs for LC-MS analysis and MS technology.
Today, we can draw three main bricks of life, genome, proteome, and metabo-
lome (Figure 1), respectively, and to determine nucleic acids, proteins, and 
metabolites, there are various analytical tools in which, for the last two bricks, mass 
spectrometry (MS) plays a central role. Whereas Figure 1 describes three equal 
bricks of life, the analytical tools have somehow driven DNA far ahead in terms 
of grants and publications. Indeed, Figure 2 depicts the number of publications 
collected in PubMed database for the last 20 years in relation to these three bricks, 
“genome, proteome, or metabolome” and “patients” as key words. Figure 2 reveals 
that the number of publications related to the genome is much higher (log scale) 
than for the proteome and metabolome. It underscores the efficiency of DNA chips 
(high-throughput sequencing) as analytical tools. Figure 2 also reveals the higher 
number of publication for the proteome than for the metabolome. A steady state 
between these three bricks of life is expected to come in a near future because 
genome, proteome, and metabolome have complementary information and because 
recent MS technologies with improved analytical capabilities, have been launched 
during this last decade. These recent MS are high-resolution mass spectrometers 
(HRMS) and allow cheap targeted and omics/global approaches. They should 
promote proteome and metabolome determinations not only in research but also in 
routine laboratories for diagnosis purposes (e.g., clinical and toxicology labs).
The main advantages of DNA sequencing over the determination of proteins 
and metabolites are that (1) DNA can be multiplied (PCR), (2) the DNA sequence 
is (roughly) constant over the entire life, and (3) the analysis has become really 
affordable. On the other hand, the great advantage of the determination of the 
proteome and/or the metabolome over the genome is the integration of all types of 
interactions and memories (e.g., age) that the living system has with its environ-
ment (Figure 3) [5]. This last point is crucial and supports an increasing need for 
individual’s proteome and metabolome determination.
In addition, the concepts of “long tail disease” and “tyranny of the average” have 
recently emerged (Figure 4) [6, 7]. These concepts underscore the high number 
Figure 1. 
The three mains of life, their bases, entities, and analytical tools.
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of low-prevalence diseases. Low-prevalence diseases represent a significant part of 
many diseases that are wrongly considered as homogenous (etiology or molecular 
mechanism of the disease) and would be diagnosed with many different biomark-
ers. Low-prevalence (sub-)diseases suggest that there is a need to determine more 
globally what is in the patient’s sample (the proteome and/or the metabolome) in 
order to find unexpected outsider molecules that will be at a low frequency but 
with a high significance as biomarkers. Eventually, these concepts promote medical 
doctors and bioanalysts to favor more holistic approaches for a higher consideration 
of individual (variations limiting the tyranny of the average) [6, 7].
Figure 2. 
Number of publications in PubMed database in relation to three keywords, “genomics,” “proteomics,” and 
“metabolomics,” associated to “patients” over the last two decades.
Figure 3. 
System biology and its holistic approach. The phenotype of an individual is the results of the interaction and 
memories of the genome and the environment. It sustains that a global approach is valuable in personalized medicine (adapted 
from [5]).
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These actual concepts in life sciences have become crucial for understanding the 
complexity of biological systems and for delivering better personalized diagnostics 
and medicine. It promotes the LC-MS instruments capable to record “global view” 
in one affordable analytical shot [8, 9].
2. LC-MS technologies
This can be useful to recall that liquid chromatography coupled to mass spec-
trometry (LC-MS) is composed of three parts: (1) the (U)HPLC system, (2) the 
atmospheric pressure ion (API) source (most frequently the API source type is an 
“electrospray”), and (3) the mass analyzer (Figure 5) [10]. The ion source is an 
interface between the liquid and the gas phase, where the mobile phase is vapor-
ized, leaving the ions in the gas phase and ready to enter in the MS. Even if the 
second and third parts are fully integrated, the ionization chamber can rapidly 
be changed by another source that is designed for different flow rates or modes 
of ionization. The LC-MS analysis records chromatograms where m/z values 
(ions = mass over charge ratios) are detected (relative intensity) and depicted over 
time (Figure 5). Ions are detected as positive or negative adducts: usually +H+ but 
also +Na+, K+, NH4+, and −[H+]−. There are three main MS technologies (ion trap 
MS would be the fourth but it is not described here) that can be divided in low 
and high mass resolution instruments (Figure 6). There are triple-quadrupole 
(QQQ-MS), (quadrupole-)time-of-flight-MS (TOF-MS), and (quadrupole-)
Orbitrap-MS (Orbi-MS; e.g., Q Exactive).
Most frequently, mass resolution (R) is defined as R = m/∆mFWHM, where [m] 
and ∆mFWHM correspond to the m/z of the ion considered and the distribution of m/z 
at full-width half-maximum of the peak height (FWHM), respectively (∆mFWHM 
units are Da, u, or Th; Figure 7) [11]. Mass accuracy is defined as the delta between 
the theoretical and measured m/z and is given in mDa (u or mTh) or in ppm [11]. 
Accurate mass determination allows to extract ions with narrower mass-extraction-
window (MEW) in order to construct extracted-ion chromatograms (XIC) [12].
Low- and high-resolution mass spectrometers are defined with an R value below 
or above 10,000, respectively. Low-resolution MS (LRMS) are QQQ-MS, whereas 
Figure 4. 
Prevalence of a disease “A” against disease mechanisms. The figure depicts a long tail curve suggesting that, 
beside the frequent and few molecular mechanisms or origins of the disease (left part of the curve), there 
are many low-prevalence subcategories of the “same” disease (right part of the curve). In this scenario, the 
determination of a few usual biomarkers can be useless for many patients. The potential high number of 
biomarkers with low prevalence but high significance suggests that untargeted acquisition and untargeted data 
treatment have their place in biomedical analyses.
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high-resolution MS (HRMS) are TOF-MS and Orbi-MS instruments. It is worth to 
note that R is not a constant value over the mass range (Figure 8) [12]. R values are 
usually given at m/z = 200 and 400 for Orbi-MS and TOF-MS, respectively. Today, R 
Figure 5. 
LC-MS analysis. LC-MS systems are composed of a LC part, an ion source, and a MS analyzer. LC-MS 
analysis is defined mainly by a retention time, a relative intensity (arbitrary units), and the ions detected (m/z, 
mass over charge ratio).
Figure 6. 
The three most frequent MS technologies and their key characteristics for scanning rate and mass resolution 
(adapted from [7]).
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varies between 20,000 and 140,000 in (U)HPLC-MS analysis for m/z between 100 
and 800. Orbi-MS has a higher R allowing a better discrimination of ions (e.g., fine 
isotopic distribution).
This is also of interest to know that there are slow and fast-scanning MS. In scan 
mode (e.g., m/z ranging from 100 to 1000), QQQ-MS are slow and insensitive. For 
this reason, the acquisition mode of QQQ-MS is, in most cases, selected reaction 
monitoring (SRM; also called multiple reaction monitoring, MRM). In SRM acqui-
sition, the precursor ion is selected in the first quadrupole (Q1) and fragmented in 
the collision cell (Q2), and an intense and specific fragment/product ion is selected 
Figure 7. 
Sketch showing what are the mass resolution and the mass accuracy. Typical mass resolution and mass accuracy 
are exemplified. m/zmeas and m/ztheor stand for measured and theoretical m/z (adapted from [6]).
Figure 8. 
Mass resolution (R) against the m/z range for the three most frequent MS technologies (adapted from [6]).
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in the last quadrupole (Q3) prior its detection by the photomultiplier. This is an ion 
transition please, see Figures 6 and 9. In contrast, TOF- and Orbi-MS are fast-
scanning instruments. Scan rates of affordable Orbi-MS depend on the resolution 
chosen and are typically 1.5, 3, 6, and 12 Hz (number of scans/s) at R = 140,000, 
70,000, 35,000, and 17,500 (at m/z = 200), respectively. TOF has a higher scan rate 
(>20 Hz) which can be an advantage if multiple acquisitions are recorded in parallel 
or if ion mobility is used. The main differences between the three most frequent 
technologies, QQQ-, Orbi-, and TOF-MS, are depicted in Figure 6 and Table 1.
Figure 10 sketches the key consequence of the differences between QQQ-MS, 
on one side, and TOF- and Orbi-MS, on the other side. This is related to the 
acquisition types that are ion transitions (SRM) and high-resolution full scan 
(HR-full scan). QQQ-MS have to acquire SRM in order to be selective and sensi-
tive, whereas TOF- and Orbi-MS are selective and sensitive in the full-scan mode 
acquisition [13]. This means that with SRM acquisition, the bioanalyst has to 
know the precursor and product ions and the collision energies to apply prior 
to the analytical run. In contrast, with HRMS full-scan acquisition, the bioana-
lyst can use generic parameters and acquire all ions in a large mass range (e.g., 
m/z from 100 to 1000) Figure 9. In this last scenario, a global determination is 
recorded allowing various kinds of retrospective, targeted, or untargeted data 
treatments. In this book chapter, we have defined the global ion acquisition as 
the HR-full scan, whereas there are various alternative possibilities defined as 
data-independent acquisitions (DIA; e.g., MSALL, MSE, MSSWATH) that also record 
virtually all ions [14, 15].
A good example of retrospective data mining is shown in the biotransforma-
tion study of tamoxifen [16]. In this study, plasma samples from patients treated 
with tamoxifen were extracted and analyzed with a LC-HRMS acquiring HR-full 
scan. Retrospective data treatment allowed to detect and determine 39 tamoxifen 
metabolites. A second example of post-acquisition data mining is shown in an 
Figure 9. 
Typical acquisitions for sensitive and selective detections with low- and high-resolution MS: ion transitions 
(QQQ-MS) and full scan (HRMS), respectively.
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Figure 10. 
Usual acquisitions for sensitive and selective detections on QQQ-MS and HRMS analyses. With QQQ-MS, ion 
transitions have to be defined before the analysis. Therefore, the selective filter is applied before the acquisition. 
With HRMS, the acquisition can be performed in full-scan mode where, virtually, “all” ions are recorded. The 
selective filter is applied after the acquisition by choosing the ions to be extracted. Typical QQQ- and HRMS 
acquisitions are depicted on the chromatograms.
untargeted diagnostic screening workflow where an outlier metabolite in a patient’s 
metabolome is revealed by the comparison with healthy people metabolomes [17]. 
Both examples are better described in Section 3.
Importantly, like for QQQ-MS, most actual HRMS can perform excellent 
quantitative determinations (see the following section) [13]. This is why today’s 
HRMS instruments should be considered as the new gold standard in LC-MS 
analyses because of their capabilities to perform quantitative, qualitative, quan/
qual, and omics analyses (Figure 11) [13]. As depicted in Table 1, quantita-
tive performance of HRMS is not better but equivalent to QQQ-MS. But the 
Table 1. 
Key analytical differences of the most frequently used mass spectrometers. This table allocates a grade according 
to global or targeted MS performance (one to five points for poor to excellent, respectively). Global acquisition 
(*) corresponds to high-resolution full scan or data-independent acquisition (no selection of precursor ions). 
Targeted acquisition (**) corresponds to SRM (selected reaction monitoring) or product ion scan (selection of 
precursor ions). The last row gives the sum of the grades (adapted from [7]).
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HRMS-unique capability to perform global and qualitative analyses is becoming 
more and more crucial. For one or two decades, the mind-set of bioanalysts 
performing LC-MS analysis was the following: QQQ-MS are the instruments of 
choice for routine and quantitative analyses, whereas complex and expensive 
HRMS instruments are dedicated to qualitative and research analyses. This 
is outdated. With the recent progress in HRMS technologies (both TOF and 
Orbi-MS), a shift of paradigm is occurring [8, 12, 18]. This shift of paradigm 
is based on the fact that today’s HRMS instruments can perform both excellent 
quantitative and qualitative analyses. HRMS should be seen as the new gold 
standard mass analyzers (Figure 11).
In the next section, typical examples of LC-HRMS analyses are presented. 
HRMS represents the most versatile analytical tool allowing to perform from 
targeted quantification to untargeted metabolomics/proteomics [13].
3. Examples of quantitative and qualitative LC-HRMS analyses
3.1 Quantitative performance of HRMS instruments
Today, there are many peer-review articles that compare side-by-side the 
quantitative performance of QQQ-MS and HRMS instruments [19–26]. These 
comparisons investigate the sensibility, selectivity, ease of use, calibration linearity, 
reliability, and robustness in real-life LC-MS analyses. This is always difficult to 
have an absolute comparison between two MS technologies because it is related to 
various parameters like the compounds studied, the two ion source designs (not the 
MS itself) that possibly show different sensitivities, the memory effects on column 
that perturb the determination of the limit of detection, the different generations 
of lenses/ion guides that are just behind the entrance of the MS and that usually are 
independent to MS technologies, etc. The frequently claimed better sensitivity of 
QQQ-MS over other technologies is often the result of latest hardware modifications 
(more efficient lenses, ion guides, etc.) introduced first in new QQQ-MS. Again, 
this is not related to the mass analyzer itself.
Figure 11. 
Overview of the analytical workflows performed by QQQ-MS and HRMS. Box sizes relate to the analytical 
performance. Whereas quantitative (quan) determination is similar between LRMS (SRM; QQQ-MS) and 
HRMS (TOF-, Orbi-MS; HR-full scan), HRMS has much better analytical capabilities for qualitative (qual), 
simultaneous quantitative and qualitative (quan/qual), and omics (targeted and untargeted metabolomics and 
proteomics) workflows.
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Nevertheless, a general conclusion can be drawn from these numerous articles 
and comparisons. Today, most HRMS instruments show similar quantitative 
performance than QQQ-MS [13, 19–26]. In Figures 12–14, adapted from recent 
publications (respectively Refs. [25] and [23]), the authors underscore that HRMS 
quantitative performance is comparable to QQQ-MS. Figure 12 depicts LC-MS 
chromatograms at the limit of detection, the calibration curves, and the fold dif-
ferences of the limits of detection obtained for nine drugs with a QQQ-MS (TSQ 
Quantum Ultra) performing ion transitions (SRM) and a HRMS (Q Exactive Focus) 
performing HR-full scans. No significant differences of quantitative performance 
were observed except the saturation of the QQQ-MS detector at the highest spiked 
concentrations (5000 ng/mL corresponding to 10 ng on column) [25]. Figure 13 
depicts the limits of quantification (LOQ ) of 27 compounds determined in SRM 
and full scan with a QQQ-MS and a HRMS [23]. Here again, no significant dif-
ferences in the LOQ values were observed [23]. As shown in Figure 13, the fold 
differences between QQQ-MS and Orbi-MS are below ≈3x (or 1/3x) for 22/27 
compounds. Four compounds show a more pronounced difference, between 7x 
and 20x, in favor of HRMS, which is probably the result of poor intensity of the 
fragment ions (SRM acquisition). In contrast, one compound shows a better LOQ 
value (8x) with the QQQ-MS. Figure 14 shows the reliability of 25-hydroxyvitamin 
D3 quantification in 662 serum extracts analyzed with a QQQ-MS (SRM) and an 
Orbi-MS (HR-full scan) [27], exemplifying the robustness of HRMS in routine and 
quantitative determinations (see also [28, 29]). Similar conclusions showing the 
Figure 12. 
Example of side-by-side comparison of LC-MS quantification with QQQ-MS and HRMS. Chromatograms 
at the limit of detection (LOD) in plasma extracts, curve linearities, and LOD differences between both 
MS platforms are depicted, whereas QQQ-MS and HRMS acquire SRM and HR-full scan, respectively. 
Calibration curves at the lowest levels are similar, whereas at the highest levels, a saturation of the QQQ-MS 
multiplier is observed. (*) ratio < 1 means QQQ-MS is more sensitive than HRMS and vice versa (adapted 
from [14]).
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capability of routine determinations have been made for Q-TOF-MS [20, 30, 31]. 
If needed (e.g., poorly cleaned sample extracts or direct-flow-injection analysis), 
the acquisition of fragment ions can show higher selectivity or/and sensitivity in 
LC-HRMS analysis [25, 32].
Figure 14. 
Passing and Bablok fit of 25-hydroxyvitamin D3 in 662 plasma extracts determined with QQQ-MS and HRMS 
acquiring SRM and full scan (adapted from [16]).
Figure 13. 
Example of side-by-side comparison of LC-MS quantification with QQQ-MS and HRMS. Limits of 
quantification for 27 compounds are plotted in biological extracts. Most compounds show similar LOQ values 
(differences <3x), whereas four compounds with probable poor intensity of the fragment ions show lower LOQ 
values with QQQ-MS (adapted from [20]).
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Evidences of HRMS quantitative performance are accumulating [13], but this 
is not straightforward to change bioanalysts’ habits that have used QQQ-MS for 
decades. It can be difficult to convince them to shift, whereas HRMS shows “only” 
similar quantitative performance as QQQ-MS. The shift in favor of HRMS still needs 
activation energy in order to occur. This activation energy will come from the addi-
tional and outstanding capabilities of HRMS for qualitative and untargeted determi-
nations and the increasing needs for more global and/or untargeted approaches in the 
determination of biological samples [33]. Even if some laboratories will concentrate 
their work exclusively on targeted and quantitative analyses and will possibly keep 
working with predefined ion transitions on QQQ-MS, most lab heads will “feel” the 
additional needs for untargeted acquisitions and untargeted data treatments for rou-
tine or investigation analyses (see Introduction section and the following section). 
Here below, quan/qual, qualitative, and omics analysis are presented.
3.2 Quan/qual and qualitative analyses with HRMS instruments
The in vivo biotransformation study of tamoxifen represents a good example of 
quan/qual analysis [16]. Tamoxifen is a selective estrogen receptor modulator, used 
for the prevention and adjuvant treatment of estrogen-sensitive breast cancer. In 
this study, plasma samples from patients treated with tamoxifen (steady-state lev-
els) were analyzed with a QQQ-MS (TSQ Quantum Ultra; SRM acquisition) or with 
an Orbi-MS (Exactive Plus MS; HR-full-scan acquisition). It has been shown that 
tamoxifen metabolites can be more active than the parent drug and that tamoxifen 
reactive metabolites can bind to macromolecules [33]. It was and is challenging 
to reveal new findings with tamoxifen because hundreds of articles have already 
studied in vivo and in vitro the biotransformations of tamoxifen [21].
First, in this study [16], similar plasma levels (CV < 15%) of tamoxifen and two 
metabolites were obtained with the QQQ-MS and the HRMS platforms. Secondly, the 
HR-full-scan acquisition allowed the identification of 39 circulating metabolites of 
tamoxifen, of which 3 were never described previously and corresponded to the sixth 
and seventh generations (6 and 7 biotransformation steps; Figure 15). Semiquantitative 
determinations of tamoxifen metabolites allowed to observe that some metabolites have 
a high plasma level variability with poor relations with the parent drug level, whereas, 
in contrast, other metabolites show a strong relation to tamoxifen levels (Figure 15). 
Various strategies were employed to identify tamoxifen metabolites. They consisted 
in the extraction of ions from possible biotransformation pathways (and chemical 
compositions) or from similar tamoxifen fragmention (Figure 15). All these tasks were 
particularly simplified because of the HRMS detection selectivity (accurate mass and 
high-resolution spectra allowing narrow mass-extraction-windows) and because of 
the sensitivity of HR-full scan or MSALL acquisitions (product scan where all precursor 
ions are fragmented, no selection of precursor ions in the quadrupole; see also data-
independent acquisition, MSSWATH, or MSE acquisitions [13]).
This study [16] demonstrates the excellent capabilities of HRMS data for further 
investigations in real biological samples on top of the targeted and quantitative deter-
minations of tamoxifen and two metabolites. Similarly, from HR-full-scan acquisi-
tion, new metabolites of hepcidin, a peptide involved in iron homeostasis in the blood, 
have been discovered on the side of the quantitative determination of hepcidin [28]. It 
underscores that HR-full-scan acquisitions allow targeted simultaneous and quantita-
tive determinations and investigational data treatment (see also [14, 34–37]).
3.3 Omics analyses with HRMS instruments
In general, LC-MS omics analyses (metabolomics and proteomics) are associated 
to research analyses such as the discovery of biomarkers. In the new understanding 
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of life sciences where a holistic approach has its place in routine analysis and 
where low-prevalence diseases represent a significant part (Figure 4), there is an 
increasing need for untargeted or semi-targeted LC-MS analysis as a diagnostic 
workflow. Here below, an untargeted diagnostic screening is presented as a metabo-
lomics analysis [17]. This study evaluates the feasibility to perform an untargeted 
LC-HRMS analysis and an untargeted data treatment in a routine context.
Figure 16 depicts this study [17] and its omics workflow. One serum sample (the 
test sample) was spiked with one compound. The serum sample was then extracted 
(protein precipitation) and analyzed with a LC-HRMS system acquiring HR-full 
scan from m/z 60 to 900 (untargeted acquisition) this sample was compared with 
95 samples from healthy persons. Unsupervised (untargeted) data treatment with 
a metabolomics software allowed, after the application of different filters that 
remove insignificant ions (>99%), to reveal the spiked compound in a short and 
final list of 20–50 compounds (the number of detected ions is >10,000). Whereas, 
in the final list, many ions were not identified (e.g., unknown adducts, isotopes, 
or in-source fragments) or were compounds from food intake; this untargeted 
diagnostic screening procedure appears feasible and reliable to reveal unexpected 
xenobiotics (toxicology) or higher concentrations of endogenous metabolites. 
Correlation(s) between clinical symptoms and metabolite outlier(s) found in a 
patient should be done by clinicians prior to the request for a confirmatory, tar-
geted, and absolute quantification analysis. Such HRMS untargeted approaches 
could be useful as preliminary diagnostic screening when canonical and targeted 
processes do not establish nor reveal a clear diagnostics or disease etiology (low-
prevalence disease mechanism or etiology). Similar examples that underscore 
or suggest the utility of untargeted acquisitions in routine analyses have been 
published [38, 39].
Figure 15. 
Biotransformation study of tamoxifen. Left-hand side: correlations between tamoxifen levels and two 
of its metabolites showing poor (top) and good (bottom) R2 coefficient. Right-hand side: top, tamoxifen 
fragmentation; accurate mass determination allow to assign chemical compositions and putative chemical 
structures to tamoxifen fragments; bottom: in-depth coverage of tamoxifen metabolite discovery resulting from 
HR scans and accurate mass extractions of ions (adapted from [9]).
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4. Conclusion and perspectives
In this book chapter, a brief review of the performance of HRMS instruments 
has been presented: first, on quantitative and then on qualitative, quan/qual, and 
omics analyses. Today, there are numerous peer-review articles showing that in 
quantitative analysis, most actual HRMS instruments are performing similarly to 
QQQ-MS. Taken into account the additional and unique HRMS capabilities for 
qualitative and untargeted determinations, HRMS opens new analytical possibilities 
that fit new requests from systems biology and its holistic/global approaches. For this 
reason, HRMS should be considered as the new gold standard MS systems (paradigm 
shift). Indeed, HRMS shows unique versatility, and bioanalysts can foresee routine or 
research analyses from targeted quantifications to untargeted metabolomics.
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Figure 16. 
Untargeted diagnostics screening workflow. The metabolome of a human serum (containing a spiked molecule, 
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analysis can be undertaken when canonical procedures fail. This workflow is in accordance with “low-
prevalence diseases” and against the “tyranny of the average” concepts (adapted from [8]).
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